Trial reportBioMed research international2014
Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world.
Trial report in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 87 citations in OpenAlex.
- GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis.Annals of the rheumatic diseases · 2020Trial
- Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.Arthritis research & therapy · 2018Trial
- Construct validity and responsiveness of EQ-5D-3L and EQ VAS in psoriatic arthritis: an evaluation based on the Swedish Rheumatology Quality Register.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Matrix Metalloproteinase-9 as a Biomarker for Diagnosis and Monitor Disease Progression in Psoriatic Arthritis.Mediterranean journal of rheumatology · 2025Article
- Cardiometabolic Risk in Psoriatic Arthritis: A Hidden Burden of Inflammation and Metabolic Dysregulation.Metabolites · 2025Review
- Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post-marketing surveillance study.The Journal of dermatology · 2024Article
- Machine learning identifies right index finger tenderness as key signal of DAS28-CRP based psoriatic arthritis activity.Scientific reports · 2023Article
- Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort.Advances in rheumatology (London, England) · 2023Article
- Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis.Frontiers in medicine · 2023Article
- A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal study.BMC health services research · 2022Observational
- Article
- Consensus statements for evaluation and nonpharmacological Management of Psoriatic Arthritis in UAE.International journal of rheumatic diseases · 2022Review
- The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the 'GO-UP' study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022Article
- Article
- Assessment of subclinical atherosclerosis with ankle-brachial index in psoriatic arthritis: A case-control study.Archives of rheumatology · 2021Article
- Knowledge of disease, diagnosis, adherence and impact of research in an Irish cohort of patients with inflammatory arthritis.HRB open research · 2021Article
- Predicting functional disability in patients with spondyloarthritis using a CRP-based algorithm: A 3-year prospective study.Experimental and therapeutic medicine · 2021Article
- Living with arthritis: a "training camp" for coping with stressful events? A survey on resilience of arthritis patients following the COVID-19 pandemic.Clinical rheumatology · 2020Article
- Measuring Outcomes in Psoriatic Arthritis.Arthritis care & research · 2020Review
- Mediterranean diet and Psoriatic Arthritis activity: a multicenter cross-sectional study.Rheumatology international · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare, "in a real world," the performance of the most common composite activity indices in a cohort of PsA patients.
methodsA total of 171 PsA patients were involved. The following variables were evaluated: peripheral joint assessment, patient reported of pain, physician and patient assessments of disease activity, patient general health status, dactylitis digit count, Leeds Enthesitis Index, Health Assessment Questionnaire (HAQ), physical and mental component summary score of the Medical Outcome Survey (SF-36), Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). To measure the disease activity, the Disease Activity Score (DAS28-ESR and DAS28-CRP), Simple Disease Activity Index (SDAI), Composite Psoriatic Disease Activity Index (CPDAI), disease activity in psoriatic arthritis (DAPSA), and Psoriatic Arthritis Disease Activity Score (PASDAS) have been calculated. The criteria for minimal disease activity (MDA) and remission were applied as external criterion.
resultsThe ROC were similar in all the composite measures. Only the CPDAI showed less discriminative ability. There was a high degree of correlation between all the indices (P < 0.0001). The highest correlations were between DAPSA and SDAI (rho = 0.996) and between DAPSA and DAS28-CRP (rho = 0.957). CPDAI, DAPSA, and PASDAS had the most stringent definitions of remission and MDA category. DAS28-ESR and DAS28-CRP had the highest proportions in remission and MDA.
conclusionsAlthough a good concurrent validity and discriminant capacity of six disease activity indices were observed, the proportions of patients classified in the disease activity levels differed. In particular, the rate of patients in remission was clearly different among the respective indices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.